newsfilter
← Latest News
GlobeNewswire·

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3 tri-specific